IOVA Archives - Page 11 of 12

1 minute read

Iovance Biotherapeutics Acquires Clinigen’s IL-2 Product For Upfront £166.7M

January 23, 12:39 PM

Iovance Biotherapeutics Inc (NASDAQ:IOVA) has agreed to acquire worldwide rights to Proleukin (aldesleukin), an interleukin-2 (IL-2) product, from Clinigen Limited. Iovance expects…

IOVA

1 minute read

Analyst Ratings

What 6 Analyst Ratings Have To Say About Iovance Biotherapeutics

By Benzinga Insights

December 9, 11:07 AM

Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

IOVA

1 minute read

Goldman Sachs Downgrades Iovance Biotherapeutics to Neutral, Lowers Price Target to $6

By Benzinga Newsdesk

December 9, 9:11 AM

Goldman Sachs analyst Madhu Kumar downgrades Iovance Biotherapeutics (NASDAQ:IOVA) from Buy to Neutral and lowers the price target from $20 to $6.

IOVA

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

December 5, 1:31 PM

Gainers Nymox Pharmaceutical (NASDAQ:NYMX) shares increased by 32.7% to $0.38 during Monday’s regular session. As of 12:30 EST,…

AMPE

1 minute read

Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate

By Vandana Singh

November 18, 1:09 PM

Iovance Biotherapeutics Inc (NASDAQ:IOVA) announced that its ongoing rolling Biologics License Application (BLA) submission to the FDA for lifileucel…

IOVA

31 minute read

Earnings

Earnings Scheduled For November 3, 2022

By Benzinga Insights

November 3, 5:42 AM

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

AAOI

9 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 31, 2022

By Benzinga Insights

October 31, 10:13 AM

Upgrades

ABCB

1 minute read

Guggenheim Initiates Coverage On Iovance Biotherapeutics with Neutral Rating

By Benzinga Newsdesk

October 31, 9:54 AM

Guggenheim analyst Kelsey Goodwin initiates coverage on Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral rating.

IOVA

1 minute read

Iovance Biotherapeutics Announces First Patient Dosed With PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy

By Bill Haddad

October 10, 7:30 AM

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that the first patient was dosed, and completed the safety observation

IOVA

2 minute read

Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 25, 6:43 PM

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F…

APTX

Feed Symbols: IOVA